Iopamidol
Star0
Identification
- Summary
Iopamidol is a diagnostic imaging agent used for angiography throughout the cardiovascular system.
- Brand Names
- Isovue 200, Isovue 250, Isovue 300, Isovue 370, Isovue-M, Isovue-M 200
- Generic Name
- Iopamidol
- DrugBank Accession Number
- DB08947
- Background
Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 777.0853
Monoisotopic: 776.854094955 - Chemical Formula
- C17H22I3N3O8
- Synonyms
- Iopamidol
- Iopamidolum
- External IDs
- B 15 000
- SQ 13,396
- SQ 13396
- SQ-13396
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAldesleukin The risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin. Metformin The risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Gastromiro (Bracco) / Iopamiro (Bracco) / Iopamiron (Bayer) / Jopamiro (Bracco) / Moiopamin (Hikari Seiyaku) / Oypalomin (Fuji Yakuhin) / Solutrast (Bracco)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Iopamidol Injection USP Solution 76 % Intravascular Hospira Healthcare Ulc Not applicable Not applicable Canada Iopamidol Injection USP Solution 61 % Intravascular Hospira Healthcare Ulc Not applicable Not applicable Canada Isovue Solution 612 mg/1mL Intravascular Apothecary Shop Wholesale Inc. 2011-07-01 2011-08-31 US Isovue 128 Inj 26% Liquid 26 % Intravenous Squibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc. 1988-12-31 1998-07-30 Canada Isovue 128 Injection Liquid 26 % Intravenous Bracco Imaging S.P.A. 1998-01-08 2000-07-20 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Iopamidol Injection, solution 612 mg/1mL Intravascular Slate Run Pharmaceuticals, Llc 2024-04-15 Not applicable US Iopamidol Injection, solution 612 mg/1mL Intrathecal Slate Run Pharmaceuticals 2023-07-20 Not applicable US Iopamidol Injection, solution 510 mg/1mL Intravascular Slate Run Pharmaceuticals, Llc 2024-04-15 Not applicable US Iopamidol Injection, solution 408 mg/1mL Intrathecal Slate Run Pharmaceuticals 2023-07-20 Not applicable US Iopamidol Injection, solution 755 mg/1mL Intravascular Slate Run Pharmaceuticals, Llc 2024-04-15 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image PAMIRAY 370 ENJ.SOL.100 ML. Iopamidol (0.755 g/ml) Solution Intravenous BİEM İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey PAMIRAY 370 ENJ.SOL.50 ML. Iopamidol (0.755 g/ml) Solution Intravenous BİEM İLAÇ SAN. VE TİC. A.Ş. 2017-05-02 Not applicable Turkey
Categories
- ATC Codes
- V08AB04 — Iopamidol
- Drug Categories
- Acids, Carbocyclic
- Benzene Derivatives
- Benzoates
- Compounds used in a research, industrial, or household setting
- Contrast Media
- Diagnostic Uses of Chemicals
- Iodinated Contrast Agents
- Iodobenzoates
- Radiographic Contrast Agent
- Roentgenography
- Triiodobenzoic Acids
- Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media
- X-Ray Contrast Activity
- X-Ray Contrast Media, Iodinated
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as iodobenzenes. These are aromatic compounds containing one or more iodine atoms attached to a benzene.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Halobenzenes
- Direct Parent
- Iodobenzenes
- Alternative Parents
- Aryl iodides / Secondary alcohols / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organoiodides / Hydrocarbon derivatives
- Substituents
- Alcohol / Aromatic homomonocyclic compound / Aryl halide / Aryl iodide / Carboximidic acid / Carboximidic acid derivative / Hydrocarbon derivative / Iodobenzene / Organic 1,3-dipolar compound / Organic nitrogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- organoiodine compound, benzenedicarboxamide, pentol (CHEBI:31711)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- JR13W81H44
- CAS number
- 60166-93-0
- InChI Key
- XQZXYNRDCRIARQ-LURJTMIESA-N
- InChI
- InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1
- IUPAC Name
- N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-[(2S)-2-hydroxypropanamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
- SMILES
- C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I
References
- General References
- Tian FX, Xu B, Lin YL, Hu CY, Zhang TY, Gao NY: Photodegradation kinetics of iopamidol by UV irradiation and enhanced formation of iodinated disinfection by-products in sequential oxidation processes. Water Res. 2014 Jul 1;58:198-208. doi: 10.1016/j.watres.2014.03.069. Epub 2014 Apr 5. [Article]
- External Links
- KEGG Drug
- D01797
- PubChem Compound
- 65492
- PubChem Substance
- 310264913
- ChemSpider
- 58940
- 5966
- ChEBI
- 31711
- ChEMBL
- CHEMBL1200932
- ZINC
- ZINC000003830947
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Iopamidol
- FDA label
- Download (715 KB)
- MSDS
- Download (133 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Other Hypothyroidism 1 4 Completed Not Available CIN 1 4 Completed Not Available Drug Safety 1 4 Completed Not Available IV Contrast Dosing 1 4 Completed Not Available Kidney Diseases 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral; Rectal 61.2 % Solution Oral Solution Intra-arterial; Intravenous 370 mg Solution Intravenous 370 mg Solution Intra-arterial; Intravenous 612.4 mg Solution Intravenous 612.4 mg Solution Intra-arterial; Intra-articular; Intrathecal; Intravenous 300 mg Solution Intravascular 61 % Solution Intravascular 76 % Injection, solution Injection, solution Intravenous 200 mg/mL Injection, solution Intravenous 300 mg/mL Injection, solution Parenteral 150 MG/ML Injection, solution Parenteral 200 MG/ML Injection, solution Parenteral 300 MG/ML Injection, solution Parenteral 370 MG/ML Solution 300 mg/1ml Solution Intrathecal; Intravascular 61.24 g/100ml Injection Intravenous; Other 6.12 g/10ml Solution 370 mg/1ml Solution Intrathecal; Intravascular 75.53 g/100ml Injection Intravenous; Other 7.55 g/10ml Solution Parenteral 408.3 mg Solution Parenteral 755.3 mg Injection, solution Intravenous; Parenteral 61.2 % Injection, solution Intravenous; Parenteral 75.5 % Injection, solution Parenteral 408 MG/ML Injection, solution Parenteral 612 MG/ML Injection, solution Parenteral 755 MG/ML Solution Intravascular 612 mg/1mL Liquid Intravenous 26 % Injection, solution Intravascular 408 mg/1mL Liquid Intravenous 41 % Solution Intravascular; Subarachnoid 41 % Injection, solution Intravascular 510 mg/1mL Injection, solution Intravascular 612 mg/1mL Injection, solution Intravenous 612 mg/1mL Liquid Intravenous 61 % Liquid Intravascular 61 % Injection, solution Intravascular 755 mg/1mL Injection, solution Intravenous 755 mg/1mL Liquid Intravenous 76 % Liquid Intravascular 76 % Injection, solution Intrathecal 612 mg/1mL Injection, solution Intrathecal 408 mg/1mL Solution Intrathecal 408 mg/1mL Solution Intrathecal 612 mg/1mL Injection, solution Parenteral Injection Parenteral Solution Parenteral Solution Intravenous 0.612 g/ml Solution Intravenous 0.755 g/ml Liquid Intravenous 300 mg / mL Liquid Intravenous 370 mg / mL Liquid Intravenous; Subarachnoid 200 mg / mL Injection, solution Parenteral 694 mg/ml Injection, solution 150 mg/1ml Injection, solution 300 mg/1ml Injection, solution 370 mg/1ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.79 mg/mL ALOGPS logP -2.3 ALOGPS logP -0.74 Chemaxon logS -3 ALOGPS pKa (Strongest Acidic) 11 Chemaxon pKa (Strongest Basic) -2.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 8 Chemaxon Polar Surface Area 188.45 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 139.66 m3·mol-1 Chemaxon Polarizability 54.78 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 224.68802 predictedDeepCCS 1.0 (2019) [M+H]+ 227.04602 predictedDeepCCS 1.0 (2019) [M+Na]+ 233.13918 predictedDeepCCS 1.0 (2019)
Drug created at May 27, 2014 16:50 / Updated at May 21, 2024 02:58